First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat
- Written by PR Newswire
STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. This milestone marks an important step toward a new treatment for the approximately 190 million...
Read more: First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat














